GSK plc (GLAXF)

USD 20.85

(0.63%)

Revenue Summary of GSK plc

  • GSK plc's latest annual revenue in 2023 was 30.32 Billion GBP , up 3.42% from previous year.
  • GSK plc's latest quarterly revenue in 2024 Q1 was 7.36 Billion GBP , down -8.56% from previous quarter.
  • GSK plc reported a annual revenue of 29.32 Billion GBP in annual revenue 2022, down -14.04% from previous year.
  • GSK plc reported a annual revenue of 34.11 Billion GBP in annual revenue 2021, up 0.04% from previous year.
  • GSK plc reported a quarterly revenue of 7.36 Billion GBP for 2024 Q1, down -8.56% from previous quarter.
  • GSK plc reported a quarterly revenue of 8.01 Billion GBP for 2024 Q3, up 1.62% from previous quarter.

Annual Revenue Chart of GSK plc (2023 - 1989)

Historical Annual Revenue of GSK plc (2023 - 1989)

Year Revenue Revenue Growth
2023 30.32 Billion GBP 3.42%
2022 29.32 Billion GBP -14.04%
2021 34.11 Billion GBP 0.04%
2020 34.09 Billion GBP 1.02%
2019 33.75 Billion GBP 9.52%
2018 30.82 Billion GBP 2.1%
2017 30.18 Billion GBP 8.24%
2016 27.88 Billion GBP 16.58%
2015 23.92 Billion GBP 3.99%
2014 23 Billion GBP -13.2%
2013 26.5 Billion GBP 0.28%
2012 26.43 Billion GBP -3.49%
2011 27.38 Billion GBP -3.54%
2010 28.39 Billion GBP 0.08%
2009 28.36 Billion GBP 16.49%
2008 24.35 Billion GBP 7.2%
2007 22.71 Billion GBP -2.19%
2006 23.22 Billion GBP 7.23%
2005 21.66 Billion GBP 8.38%
2004 19.98 Billion GBP -6.79%
2003 21.44 Billion GBP 1.08%
2002 21.21 Billion GBP 3.3%
2001 20.53 Billion GBP 13.58%
2000 18.07 Billion GBP 112.94%
1999 8.49 Billion GBP 6.35%
1998 7.98 Billion GBP 0.04%
1997 7.98 Billion GBP -4.33%
1996 8.34 Billion GBP -20.49%
1995 10.49 Billion GBP 85.47%
1994 5.65 Billion GBP 14.73%
1993 4.93 Billion GBP 20.36%
1992 4.09 Billion GBP 20.58%
1991 3.39 Billion GBP 6.86%
1990 3.17 Billion GBP 23.7%
1989 2.57 Billion GBP 24.82%

Peer Revenue Comparison of GSK plc

Name Revenue Revenue Difference
AstraZeneca PLC 46.91 Billion USD 35.355%
Bristol-Myers Squibb Company PFD CONV 2 45 Billion USD 32.613%
CSPC Pharmaceutical Group Limited 31.45 Billion USD 3.568%
Clarus Therapeutics Holdings, Inc. 13.95 Million USD -217195.981%
Novartis AG 46.66 Billion USD 35.002%
PT Kalbe Farma Tbk. 1.97 Billion USD -1432.341%